Skip to main content
SpringerLink
Log in

Update 2017

Das müssen Sie heute zum Prostatakarzinom wissen

Prostate Cancer — Update 2017

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Was soll in der Frühdiagnostik des Prostatakarzinoms unternommen werden? Haben Screeningmaßnahmen einen Nutzen? Welchen Stellenwert hat die Bestimmung des Prostata-spezifischen Antigens? Welche Empfehlungen zur Therapie gibt es? Wie sind die Erfolgsaussichten? Die Antworten auf diese Fragen finden Sie in diesem Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Robert-Koch-Institut. Prostatakrebs. http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Prostatakrebs/prostatakrebs_node.html (Zugriff am: 12.10.2016)

  2. Hoedemaeker RF et al. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000;164:411–5

    Article  CAS  PubMed  Google Scholar 

  3. Mottet N et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016.

  4. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Kurzversion 3.1, AWMF Registernummer: 043/022OL, http://leitlinienprogrammonkologie.de/Leitlinien.7.0.html (Zugriff am: 12.10.2016)

  5. Roobol MJ et al. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013;64:530–9

    Article  PubMed  Google Scholar 

  6. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–33

    Article  PubMed  Google Scholar 

  7. Weiner AB et al. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016

    Google Scholar 

  8. Spek A et al. PSA screening. Dtsch Med Wochenschr. 2015;140:1435–7

    Article  PubMed  Google Scholar 

  9. Herlemann A, Stief CG. Active surveillance for low-risk prostate cancer. Urologe A. 2016;55:269–81

    Article  PubMed  Google Scholar 

  10. Lellig K et al. Active surveillance of low risk prostate cancer. Urologe A. 2014;53:1031–9

    Article  CAS  PubMed  Google Scholar 

  11. van der Poel H, Klotz L, Stief CG. Management of low- and intermediate-risk prostate cancer. World J Urol. 2015;33:905–6

    Article  PubMed  Google Scholar 

  12. van der Poel H et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33:907–16

    Article  PubMed  Google Scholar 

  13. Dinh KT et al. Incidence and Predictors of Upgrading and Up Staging among 10.000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015;194:343–9

    Article  PubMed  Google Scholar 

  14. Lellig E et al. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World J Urol. 2015;33: 917–22

    Article  PubMed  Google Scholar 

  15. de Rooij M et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. European Urology. 2015

    Google Scholar 

  16. Futterer JJ et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology. 2015;68:1045–53

    Article  PubMed  Google Scholar 

  17. Otto J et al. Value of endorectal magnetic resonance imaging at 3T for the local staging of prostate cancer. Rofo. 2014;186:795–802

    Article  CAS  PubMed  Google Scholar 

  18. Ruprecht O et al. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81:456–60

    Article  PubMed  Google Scholar 

  19. Billing A et al. Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol. 2015;33:923–8

    Article  PubMed  Google Scholar 

  20. Apfelbeck M et al. Focal therapy of prostate cancer in Germany. Urologe A. 2016;55:584–92

    Article  CAS  PubMed  Google Scholar 

  21. Azzouzi AR et al. TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol 2015;33:945–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Siddiqui MM et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713–9

    Article  PubMed  Google Scholar 

  23. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology. 2007;70(6 Suppl):3–8

    Article  PubMed  Google Scholar 

  24. Haffner MC et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013; 123: 4918–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu W et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559–65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tritschler S, Ganswindt U, Stief CG. Localized intermediate- to high-risk prostate cancer. Urologe A. 2016;55:318–25

    Article  CAS  PubMed  Google Scholar 

  27. Hamdy FC et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016

    Google Scholar 

  28. Donovan JL et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016.

    Google Scholar 

  29. Trinh QD et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol. 2013;64:786–98

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wilt TJ et al. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol. 2008;180:820–9

    Article  PubMed  Google Scholar 

  31. Cornford P et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016

    Google Scholar 

  32. Ohlmann CH, Gschwend J, Miller K. Drug therapy of hormone-sensitive metastatic prostate cancer: Consensus paper of the AKO/AUO. Urologe A. 2016;55:1164–72

    Article  PubMed  Google Scholar 

  33. James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024): 1163–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Sweeney CJ et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sweeney CJ. ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006;4:588–90

    PubMed  Google Scholar 

  36. Sooriakumaran P et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2016;69:788–94

    Article  PubMed  Google Scholar 

  37. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–3

    Article  PubMed  Google Scholar 

  38. Miller K et al. Metastatic castration-resistant prostate cancer: Clinical data, new treatment options and therapy monitoring. Urologe A. 2016;55:1206–12

    Article  CAS  PubMed  Google Scholar 

  39. Fendler WP et al. Radionuclide therapy and diagnostics in urology. Urologe A. 2015;54:1025–37

    Article  CAS  PubMed  Google Scholar 

  40. Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406

    Article  CAS  PubMed  Google Scholar 

  41. Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23

    Article  CAS  PubMed  Google Scholar 

  42. Fendler WP et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2016.

    Google Scholar 

  43. Tagawa ST et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Campus Großhadern, Marchioninistraße 15, D-81377, München, Deutschland

    Annika Herlemann

  2. München, Deutschland

    Alexander Kretschmer, Maria Apfelbeck,  Stefan Tritschler,  Wolfgang Fendler,  Peter Bartenstein,  Maximilian Reiser,  Christian G. Stief &  Christian Gratzke

Authors
  1. Annika Herlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Kretschmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Apfelbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Tritschler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Fendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maximilian Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian Gratzke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annika Herlemann.

Additional information

INTERESSENKONFLIKT

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herlemann, A., Kretschmer, A., Apfelbeck, M. et al. Das müssen Sie heute zum Prostatakarzinom wissen. MMW - Fortschritte der Medizin 159, 58–65 (2017). https://doi.org/10.1007/s15006-017-9037-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9037-3

Keywords

Search

Navigation